Site search

The TRANSCEND study – testing a new medicine for kidney transplant rejection Research study

This study is testing a new medication called felzartamab for people who have received a kidney transplant and developed a type of rejection called late antibody-mediated rejection (AMR). 

LIVERAGE™ - Cirrhosis Research study

This study aims to find out whether a medicine called Survodutide helps people with non-alcoholic steatohepatitis (NASH) or metabolic associated steatohepatitis (MASH) and cirrhosis to improve their liver function.

LIVERAGE™ Research study

This study aims to find out whether a medicine called Survodutide helps people with non-alcoholic steatohepatitis (NASH) or metabolic associated steatohepatitis (MASH) and F2 or F3 stage liver fibrosis to improve their liver function.

The FORTE Study Research study

This study is to test the safety and effectiveness of FB102 in well-controlled coeliac disease (those on a strict gluten free diet) following a gluten consumption challenge.

ACTION (Acute Critical and Threatening Incidents Occurring Needlessly)

ACTION™ (Acute Critical and Threatening Incidents Occurring Needlessly) is a multi-professional program to train staff in recognising patient deterioration and act appropriately in treating the acutely unwell.

NeuronCare: An Acute Neurological Physiotherapy course

NeuronCare is a professional development and training program for early career physiotherapists that combines virtual and face-to-face training. The course runs over 5 weeks from 3 June 2026.

TRAVELLER Research study

A pre-screening study to find eligible participants for future clinical trials that test new drugs for Alzheimer’s disease.

Virtual Hospital Pilot program brings care home to more Victorians News article

Patient Linda Vella underwent a triple bypass but was able to recover at home, thanks to the Virtual Hospital Pilot program.

Need an Electronic Medical Record fix? Call our Band of Builders News article

Meet the Band of Builders (BoB), the RMH’s very own crew of clinicians driving digital transformation across Allied Health.

TRAILBLAZER-ALZ 5 Research study

This study is testing a potential new treatment called donanemab (also known as LY3002813) for people with early Alzheimer’s Disease.

Welcoming the RMH’s new Chief Transformation Officer, Professor Peter Steel News article

The Royal Melbourne Hospital (RMH) is pleased to announce the commencement of Professor Peter Steel in a landmark joint role between the RMH and the University of Melbourne.

The AUTUMN study: researching a new medicine for membranous nephropathy Research study

This study is testing a new medicine called ALXN1920 for people with a kidney disease called membranous nephropathy.

OptiTMS Research study

Optimised Transcranial Magnetic Stimulation (OptiTMS) trial for the treatment of depression investigates whether personalised brain stimulation targeting can improve outcomes for people with major depressive disorder.

RMH experts demonstrate benefits of virtual stroke care in groundbreaking research News article

An international team of stroke experts from Australia’s first Mobile Stroke Unit (MSU) have proven an innovative, virtual way of delivering care can provide outcomes that are just as good as in-person, saving time and lives. 

ONWARDS-11 Study Research study

This research study aims to get more information on how a weekly insulin (insulin icodec) helps in reducing blood sugar compared to insulin glargine, an insulin taken once daily, in adults with type 1 diabetes, who are also taking a mealtime insulin (insulin aspart). 

A clinical trial testing a new investigational medication for people living with Graves’ Disease Research study

The purpose of this study is to compare a potential new treatment with improved side effects compared to current therapies in people living with Graves’ Disease. 

The RMH and the Women’s launch new partnership to close healthcare gap between men and women News article

The Royal Melbourne Hospital and the Royal Women’s Hospital this week announced a new partnership aimed at closing gaps in diagnosis, treatment and outcomes between men and women.

The Elumina Study Research study

Almost 1 in 3 people diagnosed with depression – or Major Depressive Disorder (MDD) – do not notice an improvement in their symptoms after trying at least two of the antidepressant drugs available today. This is known as Treatment-Resistant Depression (TRD). The Elumina study is...

Atumelnant in adult participants with classic Congenital Adrenal Hyperplasia Research study

The purpose of this study is to evaluate the effect of a potential new treatment for Congenital Adrenal Hyperplasia (CAH) called atumelnant and compare it to placebo treatment.

The PARTY program giving Melbourne youth offenders a sobering reality check News article

We recently welcomed Victorian Attorney-General Sonya Kilkenny to the Royal Melbourne Hospital to highlight the success of the Prevent Alcohol and Risk Related Trauma in Youth (PARTY) Intervention Program.